Hormone receptor positive breast cancer represents the most common type of breast cancer, with endocrine therapy remaining a cornerstone of the treatment for patients with metastatic disease. The fulvestrant-anastrozole combination has been shown to be superior to any either alone in a xenograft breast cancer model. In August 2012, the results of a randomized phase III study investigating the combination of anastrozole and fulvestrant in metastatic breast cancer patients were published in The New England Journal of Medicine. Read the complete ESMO journal club article here.
Study mentioned: Mehta RS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2;367(5):435-44. PMID: 22853014
No comments:
Post a Comment